BIOVENTIX PLC

Director's Dealing • Jan 31, 2023

National Storage Mechanism | Additional information

RNS Number : 4761O

BioVentix PLC

31 January 2023

Bioventix plc

("Bioventix" or the "Company")

Director/PDMR Shareholdings and Issue of Equity

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the following Directors have dealt in the Company's ordinary shares of 5 pence each (the "Ordinary Shares"):

Director	Role	Options over Ordinary Shares exercised	Ordinary Shares sold	Sale price per Ordinary Share	Ordinary Shares held on Admission	% of issued share capital held on Admission
Ian Nicholson	Non-Executive Chairman	1,600	1,600	3,750	15,500	0.3%
Peter Harrison	Chief Executive Officer	-	57,588	3,750	359,088	6.9%
Nicholas McCooke	Non-Executive Director	2,752	2,752	3,750	-	-

The options over Ordinary Shares ("Options") were exercised at a price of 1350 pence per Ordinary Share pursuant to the Company's 2013 EMI Share Option Scheme, details of which can be found at www.bioventix.com. In addition, a current employee exercised 2,000 Options.

Issue of Equity

The Company has applied for 6,352 new Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will occur and that dealings will commence in the new Ordinary Shares on 6 February 2023. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

The total number of Ordinary Shares in issue following Admission will be 5,215,685 and the Company holds no shares in treasury. Therefore, the total number of Ordinary Shares with voting rights in the Company will be 5,215,685.

The above figure of 5,215,685 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Bioventix under the FCA's Disclosure Guidance and Transparency Rules.

For further information please contact:

Bioventix plc Peter Harrison Bruce Hiscock	Chief Executive Officer Chief Financial Officer	Tel: 01252 728 001
finnCap Ltd Geoff Nash/Simon Hicks Alice Lane	Corporate Finance ECM	Tel: 020 7220 0500

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

Ian Nicholson

2.

Reason for the Notification

a)

Position/status

Chairman

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI

213800225MHX7LZQY108

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 5 pence each

Identification code

GB00B4QVDF07

b)

Nature of the transaction

Exercise of Options over Ordinary Shares

c)

Price(s) and volume(s)

Price(s)	Volume(s)
1,350p	1,600

d)

Aggregated information:

·      Aggregated volume

·      Price

See 4(c)

e)

Date of the transaction

31 January 2023

f)

Place of the transaction

Off market transaction

1

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

Ian Nicholson

2.

Reason for the Notification

a)

Position/status

Chairman

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI

213800225MHX7LZQY108

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 5 pence each

Identification code

GB00B4QVDF07

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)	Volume(s)
3,750	1,600

d)

Aggregated information:

·      Aggregated volume

·      Price

See 4(c)

e)

Date of the transaction

31 January 2023

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

1

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

Peter Harrison

2.

Reason for the Notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI

213800225MHX7LZQY108

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 5 pence each

Identification code

GB00B4QVDF07

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)	Volume(s)
3,750p	57,558

d)

Aggregated information:

·      Aggregated volume

·      Price

See 4(c)

e)

Date of the transaction

31 January 2023

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

1

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

Nicholas McCooke

2.

Reason for the Notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI

213800225MHX7LZQY108

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 5 pence each

Identification code

GB00B4QVDF07

b)

Nature of the transaction

Exercise of Options over Ordinary Shares

c)

Price(s) and volume(s)

Price(s)	Volume(s)
1,350p	2,752

d)

Aggregated information:

·      Aggregated volume

·      Price

See 4(c)

e)

Date of the transaction

31 January 2023

f)

Place of the transaction

Off market transaction

1

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

Nicholas McCooke

2.

Reason for the Notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI

213800225MHX7LZQY108

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 5 pence each

Identification code

GB00B4QVDF07

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)	Volume(s)
3,750p	2,752

d)

Aggregated information:

·      Aggregated volume

·      Price

See 4(c)

e)

Date of the transaction

31 January 2023

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEAXFFDEEDEFA